Literature DB >> 15073464

Slowing cardiovascular disease progression in African-American patients: diabetes management.

James R Gavin1.   

Abstract

The prevalence of type 2 diabetes has grown to epidemic proportions in the United States and is disproportionately higher in certain ethnic groups. African Americans, Hispanic Americans, Native Americans, and Asian Americans have an approximately two-fold higher rate of type 2 diabetes than whites. The increased prevalence of type 2 diabetes mirrors the growing rates of overweight and obese persons in the United States. While the highest rate of diabetes occurs at age 60 years and older, the fastest growing segment of the population with type 2 diabetes is younger than age 39 years. Because most diabetes-related deaths are due to cardiovascular disease, an aggressive management strategy for type 2 diabetes must address both coronary heart disease risk factor reduction and glycemic control. Both the microvascular and macrovascular complications of type 2 diabetes can be prevented or slowed with aggressive therapy. Glycemic dysfunction can be moderated by aggressive combination therapy that focuses on the pathophysiology of diabetes in an individual patient and combines two or three oral agents, such as an insulin sensitizer with an insulin secretagogue or two insulin sensitizers with different loci of action. The goal of glycemic control is reduction of glycated hemoglobin to <7%. An appropriate management strategy should not be limited to lowering blood glucose levels alone but must also address obesity, hypertension, dyslipidemia, atherosclerosis, and the increased tendency for clotting in persons with type 2 diabetes. Treatment to reduce blood pressure to <130/80 mm Hg is recommended; to accomplish this, multiple antihypertensive agents are usually necessary. The goals for correction of dyslipidemia are to reduce low-density-lipoprotein cholesterol levels to <100 mg/dL, increase high-density-lipoprotein cholesterol levels to >40 mg/dL for men and >50 mg/dL for women, and decrease triglyceride levels to <150 mg/dL. Optimal therapy for persons with diabetes should include diet and exercise with medical nutrition therapy, lowering glycated hemoglobin with intensive glycemic control, and correcting high blood pressure and dyslipidemia with early, intensive, multidrug pharmacologic therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15073464      PMCID: PMC8109425          DOI: 10.1111/j.1524-6175.2004.03561.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  48 in total

1.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.

Authors:  T S Temelkova-Kurktschiev; C Koehler; E Henkel; W Leonhardt; K Fuecker; M Hanefeld
Journal:  Diabetes Care       Date:  2000-12       Impact factor: 19.112

2.  The double puzzle of diabetes.

Authors:  Jared Diamond
Journal:  Nature       Date:  2003-06-05       Impact factor: 49.962

Review 3.  Risk stratification in coronary artery disease and special populations.

Authors:  R O Bonow; N Bohannon; W Hazzard
Journal:  Am J Med       Date:  1996-10-08       Impact factor: 4.965

Review 4.  Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.

Authors:  David J Kudzma
Journal:  Am J Manag Care       Date:  2002-10       Impact factor: 2.229

5.  Diabetes trends in the U.S.: 1990-1998.

Authors:  A H Mokdad; E S Ford; B A Bowman; D E Nelson; M M Engelgau; F Vinicor; J S Marks
Journal:  Diabetes Care       Date:  2000-09       Impact factor: 19.112

6.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.

Authors:  J C Pickup; G D Chusney; S M Thomas; D Burt
Journal:  Life Sci       Date:  2000-06-08       Impact factor: 5.037

Review 7.  Combining sulfonylureas and other oral agents.

Authors:  M Riddle
Journal:  Am J Med       Date:  2000-04-17       Impact factor: 4.965

8.  Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism).

Authors:  Julia Steinberger; Stephen R Daniels
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Authors:  K Pyŏrälä; T R Pedersen; J Kjekshus; O Faergeman; A G Olsson; G Thorgeirsson
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

View more
  2 in total

Review 1.  Executive summary of the African-American Initiative.

Authors:  Clyde W Yancy
Journal:  MedGenMed       Date:  2007-02-08

2.  The Annual African American Conference on Diabetes: evolving program evaluation with evolving program implementation.

Authors:  Jacquelyn M Houston; Maurice Martin; Joel E Williams; Rhonda L Hill
Journal:  Prev Chronic Dis       Date:  2005-12-15       Impact factor: 2.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.